Cancer treatments and therapeutic interventions are subject to a great deal of uncertainty and involve a fair amount of trial and error. This reduces the potential clinical benefits and causes costs to shoot up. The outcome from currently available treatments can be improved, for instance by optimizing schedules, dosages, and combinations. Clinical trials could be designed virtually to produce better results with lower investment, what is referred to as in silico trials. This allow us to achieve optimal results in terms of patient survival and treatment toxicity.